RT Book, Section
A1 Siefker-Radtke, Arlene O.
A1 Czerniak, Bogdan A.
A1 Dinney, Colin P.N.
A1 McConkey, Commentary: David J.
A2 Kantarjian, Hagop M.
A2 Wolff, Robert A.
SR Print(0)
ID 1126744441
T1 Bladder Cancer
T2 The MD Anderson Manual of Medical Oncology, 3e
YR 2016
FD 2016
PB McGraw-Hill Medical
PP New York, NY
SN 9780071847940
LK accessmedicine.mhmedical.com/content.aspx?aid=1126744441
RD 2024/04/19
AB Expectant  optimism  is  now  pervading  the  field  of  urothelial  cancer  as  we  anticipate  that  we  will  soon  be  soaring  above  the  plateaus  established  with  cisplatin-based  chemotherapy  in  the  1980s  and  finally  have  new  agents  approved  for  the  treatment  of  urothelial  carcinoma.  Immune  checkpoint  inhibitors,  which  are  transforming  the  field  of  oncology,  are  showing  evidence  of  clinical  activity  in  early  clinical  trials  in  this  disease  (1).  In  addition,  there  are  several  ongoing  trials  of  targeted  agents  including  fibroblast  growth  factor  (FGF)  receptor  inhibitors  and  vascular  endothelial  growth  factor  (VEGF)  inhibitors  currently  in  clinical  trials  with  the  goal  of  obtaining  US  Food  and  Drug  Administration  (FDA)  approval.  Our  fundamental  understanding  of  the  biology  of  urothelial  cancer  is  changing  as  well,  with  molecular  characterization  suggesting  that  urothelial  cancer  is  no  longer  only  one  disease  (2).  These  nascent  technologies  suggest  we  will  soon  be  able  to  personalize  therapy  for  urothelial  cancer  and  reliably  predict  which  patients  will  benefit  from  specific  chemotherapy  and/or  other  targeted  agents,  transforming  our  current  treatment  of  urothelial  cancer.